You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Monitoring SABA dependence

SABA dependence is a key indicator of asthma control. If a patient is using their SABA more than twice per week, it could indicate poor control.*1

Compared with BUD/Form, Relvar is associated with a 10% reduction in SABA use in real-world settings.2

SABA use during 12-months follow-up2

graph showing SABA use during 12 months follow up

This graph has been independently created by GSK from the original data. The same results were first published in Averell CM, et al. Presented virtually at the American College of Allergy, Asthma & Immunology annual meeting 2020.

man smiling on football field
What does this mean for patients like Oscar?

Without Relvar, Oscar was frequently using his SABA reliever to address symptoms. But now that he’s using his reliever less frequently, Oscar’s experiencing far fewer interruptions to his daily life!

Discover Relvar

Happy senior male wear glasses relaxing and breathing fresh air at park
Breathing Space

From educational videos to podcasts, Breathing Space is a GSK initiative designed to share the latest thinking on lung health and provide a space for pulmonologists and other respiratory specialists to gather insights and explore best practice.


*Within the last four weeks. Other important criteria include: daytime symptoms more than twice/week; any night waking due to asthma; any activity limitation due to asthma.


BUD, budesonide; CI, confidence interval; Form, formoterol; SABA, short-acting β2-agonist.

  1. GINA. Global strategy for asthma management and prevention, 2020. Available at: Accessed May 2021.
  2. Averell CM, et al. Presented virtually at the American College of Allergy, Asthma & Immunology annual meeting 2020.

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

A.G. Last updated: May 2021 PM-IE-FFV-WCNT-210004